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Dermatophytes initiate dermatophytosis, but susceptibility to infection is dictated by host genetic factors, although
the role of some of these—such as human beta-defensin 2 (hBD-2) genomic (DEFB4) copy number (CN) variation
and its induction by IL-22—remains unclear. This was investigated in this cross-sectional study in 442 unrelated
Caucasian subjects, including 195 healthy controls and 247 dermatophytosis patients who were divided into five
subgroups according to clinical presentation. DNA samples were evaluated for DEFB4 CN variation by relative
quantification using the comparative CT method, and serum hBD-2 and IL-22 levels were determined by ELISA.
DEFB4 CN in patients was significantly lower and, except in the tinea cruris subgroup, serum hBD-2 levels were
higher than in controls. The positive correlation between hBD-2 levels and DEFB4 CN observed in controls was not
detected in patients, who also had higher serum IL-22 levels that were positively correlated with hBD-2 levels.
Moreover, unlike in control subjects, the serum IL-22 level was negatively correlated with DEFB4 CN in patients.
Taken together, these findings suggest an association between decreased DEFB4 CN, elevated serum hBD-2 and IL-
22 levels, and dermatophytosis, underscoring a gene/cytokine interaction in the occurrence of this infection.
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INTRODUCTION
Dermatophytosis (Tinea) is a dermatophytic fungal infection of
keratinized tissues. Trichophyton rubrum (T. rubrum) is the
major etiologic agent for superficial dermatophytosis world-
wide (Havlickova et al., 2008), and it can adhere to and
invade superficial keratinized tissue via carbohydrate-specific
adhesins and by secreting several kinds of keratinolytic
proteases (Esquenazi et al., 2004; Grumbt et al., 2013).
However, not all individuals are equally susceptible to
dermatophytic infections (Faergemann et al., 2005), which is
dependent on the interplay of dermatophytes with
environmental and host factors. Epidemiological studies have
identified many predisposing factors for infection, such as
diabetes mellitus, psoriasis vulgaris, advanced age, and
previous injury to the nails (Nenoff et al., 2014). Family
history is also believed to be a risk factor (Ghannoum et al.,
2013), and pedigree analysis has shown autosomal dominant
inheritance of T. rubrum susceptibility (Zaias et al., 1996).
Genetic association studies have shown that susceptibility to
T. rubrum onychomycosis is reduced by the presence of HLA
DR53 and DR6 alleles (Zaitz et al., 1996; Asz-Sigall et al.,
2010) but increased by HLA-DR8 (Garcı´a-Romero et al.,
2012). In addition, a  44C/G polymorphism in the defensin
beta (DEFB) 1 gene is correlated with increased fungal
carriage (Jurevic et al., 2003).
Human beta-defensins (hBDs) are a major subfamily of
natural antimicrobial peptides with a net positive charge
encoded by the DEFB gene cluster on chromosome 8p23.1.
One member, hBD-2, is expressed by several epithelial cell
types with well-documented microbicidal activities in innate
and adaptive immunity (Yang et al., 1999; Semple and Dorin,
2012), including chemoattraction of memory T cells and
immature dendritic cells, as well as proinflammatory effects
on immune cells and human keratinocytes. The expression of
hBD-2 (encoded by DEFB4) is regulated by interactions
between microbial factors, cytokines, cell differentiation
status and type, and genetic variation among individuals
(Groth et al., 2010; Weinberg et al., 2012). The DEFB locus
is subject to extensive variation in copy number (CN), which
can range from 2 to 12 (Harder et al., 2004; Hollox, 2010),
and a strong correlation exists between the DEFB4 CN and
mRNA level (Groth et al., 2010). A high CN underlies
susceptibility to some inflammatory disorders such as
psoriasis (Hollox et al., 2008), systemic lupus erythematosus,
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and anti-neutrophil cytoplasmic antibody–associated small
vasculitis (Zhou et al., 2012), whereas a lower CN is a risk
factor for severe chronic periodontitis (Jaradat et al., 2013).
IL-22 is a glycoprotein belonging to the IL-10 cytokine
family (Dumoutier et al., 2000) whose major function is to
protect skin keratinocytes against microbes by enhancing the
expression of antimicrobial peptides, including hBD-2, as well
as metalloproteinases that eliminate invading pathogens
(Wolk et al., 2006). IL-22 synergizes with other cytokines
such as tumor necrosis factor-a to induce an innate immune
response in primary human keratinocytes against Candida
albicans infection (Eyerich et al., 2009). Several T-cell
populations and innate lymphoid cells in humans express IL-
22 (Sonnenberg et al., 2010), which regulates cells at outer-
body barriers via a transmembrane receptor complex that is
restricted to nonhematopoietic cells such as those of the skin
and tissues of the digestive and respiratory systems (Eyerich
et al., 2010). IL-22 has been implicated in a variety of human
diseases, such as inflammatory skin disorders and bowel
disease, as well as chronic infections (Nenoff et al., 2014).
Although it has been suggested that host-specific genetic
factors predispose individuals to dermatophytosis, the role of
DEFB CN variation in the occurrence of infection remains
unknown. To investigate the possibility that DEFB4 CN is
associated with T. rubrum–mediated dermatophytosis, DEFB4
CN variation, as well as serum IL-22 and hBD-2 levels, was
examined in unrelated Caucasian dermatophytosis patients
and healthy control subjects.
RESULTS
Demographic and clinical data of participants
Characteristics of the study population are shown in Table 1.
Median ages and sex distribution for the combined group of
patients and healthy control subjects were similar, and there
were no significant differences in these variables between the
tinea corporis, tinea pedis, tinea unguium, and lesions at
multiple sites subgroups and controls. However, age and sex
distributions were associated with the presence of tinea cruris
(Po0.001).
Dermatophytosis patients have lower DEFB4 CN
DEFB4 CN varied between 2 and 11 per diploid genome
(mean±SD, 4.53±1.25; median, 4; range, 2–11) in the
control group. In the combined group of patients, CN was
between 2 and 10 (mean±SD, 3.9±1.27; median, 4; range,
2–10) (Supplementary Table S2 online). The mean DEFB4 CN
in the combined group of patients was lower than that in the
control group (Po0.0001; Bonferroni-corrected). Similarly,
the distribution of DEFB4 CN differed significantly between
the combined group of patients and the controls (Po0.0001;
Bonferroni-corrected), and there was a shift toward lower CN
(p4 copies) in patients (Po0.0001 (Bonferroni-corrected);
odds ratio (OR)¼3.11, 95% confidence interval¼1.99–
4.83) (Figure 1a). A similar trend was observed in the tinea
corporis (P¼0.0018 (Bonferroni-corrected); OR¼3.25, 95%
confidence interval¼1.73–6.10), tinea cruris (P¼0.0361
(Bonferroni-corrected); OR¼ 2.57, 95% confidence
interval¼1.42–5.03), tinea pedis (P¼ 0.0219 (Bonferroni-cor-
rected); OR¼ 2.67, 95% confidence interval¼1.42–5.03),
and tinea unguium subgroups (P¼0.0016 (Bonferroni-cor-
rected); OR¼ 3.22, 95% confidence interval¼1.74–5.96), as
well as in the subgroup comprising patients with lesions at
multiple sites (P¼ 0.0029 (Bonferroni-corrected); OR¼3.79,
95% confidence interval¼1.83–7.83) (Figure 1b–f), whereas
no significant differences were detected between patient
subgroups.
Table 1. Demographic and clinical data for the dermatophytosis study population
Clinical presentation
Variables
Controls
(n¼195)
Combined group of patients
(n¼247)
Tinea corporis
(n¼ 59)
Tinea cruris
(n¼ 24)
Tinea pedis
(n¼ 61)
Tinea unguium
(n¼64)
Multiple sites1
(n¼ 39)
Age2 44 (19–75) 42 (18–75) 39 (19–75) 27.5 (18–45) 42 (21–75) 44 (19–75) 39 (18–69)
P value3 0.158 0.241 o0.001 0.364 0.480 0.165
Sex4
Male 103 (52.8) 5 126 (51.0)5 24 (40.7)6 21 (87.5)6 34 (55.7)6 31 (48.4)6 16 (41.0)6
Female 92 (47.2)5 121 (49.0)5 35 (59.3)6 3 (12.5)6 27 (44.3)6 33 (51.6)6 23 (59.0)6
P value7 0.424 0.380 o0.001 0.243 0.860 0.482
1Lesions at multiple sites, such as tinea pedis and unguium, tinea pedis and manus/manuum, or tinea manus/manuum with infected fingernails.
2Age (in years) is given as the median and range of (minimum – maximum) values.
3Mann–Whitney test (each subgroup of patients versus controls).
4Biologically defined.
5Sex data are given as n (%); i.e., the number of male (n¼ 103) or female (n¼ 92) controls divided by the total number of controls (n¼ 195) or the number of
male (n¼ 126) or female (n¼ 121) cases divided by the total number of cases (n¼247).
6Sex data are given as n (%); i.e., the percentage of men or women in each patient subgroup divided by the total number in each subgroup (e.g., in the tinea
corporis subgroup, number of men (n¼24) or women (n¼ 35) divided by the total number in the subgroup (n¼ 59)).
7Pearson’s w2 test (each subgroup of patients versus controls).
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Serum hBD-2 level is elevated in dermatophytosis patients
The serum hBD-2 level was higher in the combined group of
patients than in the control group (median, 118.16 pg ml1;
range, 59.51–195.62 vs. median, 104.49 pg ml1; range,
53.70–179.68; Po0.0001; Bonferroni-corrected) (Figure 2a)
and was also higher in patients with lesions at multiple sites
(median, 128.78 pg ml1; range, 96.33–195.62), tinea corporis
(median, 123.18 pg ml1; range, 94.25–171.06), tinea pedis
(median, 118.04 pg ml1; range, 59.51–156.61), or tinea
unguium (median, 115.08 pg ml1; range, 74.58–166.21) than
in controls (Po0.0101; Bonferroni-corrected). However, there
was no significant difference in the hBD-2 level of tinea cruris
patients (median, 105.69 pg ml1; range, 63.50–148.35) and
control subjects (P¼ 0.453). Among patient subgroups, the
hBD-2 level was highest in patients with lesions at multiple
sites, followed by the tinea corporis, tinea pedis, tinea unguium,
and tinea cruris groups (P¼ 0.0002; Bonferroni-corrected).
Serum IL-22 level is elevated in dermatophytosis patients
IL-22 was detectable (42.6 pg ml 1) in 191 of 247 (77.3%)
patients and in 101 of 195 (51.8%) controls (Po0.001)
(Figure 2b). The median serum IL-22 level in the combined
group of patients was about 3-fold higher than that in the
control group (median, 46.45 pg ml1; range, 2.60–71.18 vs.
median, 16.05 pg ml1; range, 2.60–61.03; Po0.0001; (Bon-
ferroni-corrected)), and IL-22 levels in the tinea corporis
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Figure 1. Frequency distribution of beta defensin 2 (DEFB4) copy number (CN) variation. Values are for controls (n¼195) and (a) the combined group of
dermatophytosis patients (n¼247), and patients with tinea (b) corporis (n¼59), (c) cruris (n¼24), (d) pedis (n¼61), and (e) unguium (n¼64), as well as (f) with
multiple lesions (n¼ 39). CN was rounded to the nearest integer assigned to bins ofo4, equal to 4, and 44, and the final value was one that was the same in two
assays. Odds ratios (ORs) and confidence intervals (CIs) were calculated for cases with 44 CN versus
P
cases withp4 CN. Po0.05 was significant (Bonferroni-
corrected P values).
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(median, 46.45 pg ml1; range, 2.60–69.59), tinea cruris
(median, 48.55 pg ml 1; range, 2.60–66.25), tinea pedis
(median, 47.30 pg ml1; range, 2.60–65.73), and tinea
unguium (median, 36.22 pg ml1; range, 2.60–71.18) sub-
groups, as well as in the subgroup comprising patients with
lesions at multiple sites (median, 54.07 pg ml 1; range, 2.60–
60.54), were higher than those in controls (Po0.0024;
Bonferroni-corrected), whereas no significant differences were
found among the patient subgroups (P¼ 0.603).
DEFB4 CN is negatively correlated with serum IL-22 but not with
hBD-2 levels in dermatophytosis patients
Serum hBD-2 level was positively correlated with DEFB4
CN in healthy controls (r¼0.370; 95% confidence interval
for r (Fisher’s z transformed)¼ 0.530 to 0.246; Po0.0001
(Bonferroni-corrected)); however, this was not observed in the
combined group of patients nor in any of the patient
subgroups (Figure 3a).
There was a negative correlation between DEFB4 CN and
IL-22 level in the combined group of patients (r¼ 0.480;
95% confidence interval for r (Fisher’s z transformed)¼
 0.649 to  0.397; Po0.0001 (Bonferroni-corrected)), and
in the tinea corporis (r¼ 0.392; 95% confidence interval for
r (Fisher’s z transformed)¼ 0.680 to 0.148; P¼0.024
(Bonferroni-corrected)), tinea cruris (r¼ 0.528; 95% confi-
dence interval for r (Fisher’s z transformed)¼  1.00 to
 0.174; P¼0.0386 (Bonferroni-corrected)), tinea pedis
(r¼ 0.517; 95% confidence interval for r (Fisher’s z
transformed)¼  0.829 to 0.315; P¼0.0022 (Bonferroni-
corrected)), and tinea unguium (r¼  0.584; 95% confidence
interval for r (Fisher’s z transformed)¼  0.920 to 0.418;
Po0.0001 (Bonferroni-corrected)) subgroups, as well as in
the subgroup comprising patients with multiple lesions
(r¼ 0.483; 95% confidence interval for r (Fisher’s
z transformed)¼ 0.853 to  0.201; P¼0.0342 (Bonferroni-
corrected)) (Figure 3b). When the combined group of patients
was divided into two categories of low (p4) and high (44) CN,
the serum IL-22 level for low CN was higher than in the high
CN category (median, 53.04 pg ml1; range, 2.60 71.18 vs.
median, 25.21 pg ml1; range, 2.6068.66; Po0.0001
(Bonferroni-corrected)). There was no significant correlation
between DEFB4 CN and serum IL-22 level in the control
group (r¼  0.009; 95% confidence interval for r (Fisher’s
z transformed)¼ 0.150 to 0.132; P¼0.263).
Serum IL-22 and hBD-2 levels are positively correlated in
dermatophytosis patients
IL-22 and hBD-2 levels were positively correlated in the
combined group of patients (r¼ 0.552; 95% confidence
interval for r (Fisher’s z transformed)¼0.495 to 0.747;
Po0.0001 (Bonferroni-corrected)), as well as in the tinea
corporis (r¼0.484; 95% confidence interval for r (Fisher’s z
transformed)¼ 0.266 to 0.790; P¼0.001 (Bonferroni-cor-
rected)), tinea pedis (r¼0.614; 95% confidence interval for r
(Fisher’s z transformed)¼0.458 to 0.972; Po0.0001(Bonfer-
roni-corrected)), tinea unguium (r¼ 0.640; 95% confidence
interval for r (Fisher’s z transformed)¼0.490 to 0.992;
Po0.0001 (Bonferroni-corrected)), and patients with multiple
lesions (r¼0.611; 95% confidence interval for r (Fisher’s z
transformed)¼ 0.384 to 1.00; Po0.0001 (Bonferroni-cor-
rected)) (Figure 3c), but not in the tinea cruris subgroup
(r¼0.371; 95% confidence interval for r (Fisher’s z
transformed)¼  0.038 to 0.818; P¼ 0.073) or in the controls
(r¼0.0692; 95% confidence interval for r (Fisher’s z
transformed)¼  0.073 to 0.211; P¼0.091).
DISCUSSION
The current study investigated the association between the
occurrence of superficial dermatophytosis resulting from T.
rubrum infection and DEFB4 CN variation and serum levels of
hBD-2 and IL-22. The DEFB4 CN distribution observed here in
controls (Figure 1) was consistent with earlier findings in
European populations (Hollox et al., 2008). The CN was lower
in dermatophytosis patients regardless of the clinical
presentation, which has not been previously reported, but it
is consistent with a general role of human genetic variation in
antifungal immunity (Zaitz et al., 1996; Asz-Sigall et al., 2010;
Garcı´a-Romero et al., 2012). The high CN and elevated hBD-2
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Figure 2. Serum levels of human beta defensin (hBD)-2 and interleukin (IL)-22 in dermatophytosis patients (n¼ 247) and healthy controls (n¼195). (a) Human
beta defensin (hBD)-2; (b) interleukin (IL)-22. Patient subgroups are represented by different colors. The medians are indicated by horizontal bars. Comparisons
between patient subgroups and the control group were performed with the Mann–Whitney test, and comparisons between subgroups were performed with the
Kruskal–Wallis test. Po0.05 was significant (Bonferroni-corrected P values).
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expression in psoriasis patients may also explain the relatively
low prevalence of bacterial and viral infections among those
patients (Jansen et al., 2009).
Except for those in the tinea cruris subgroup, serum hBD-2
level was higher in all patients than in controls (Figure 2).
Unexpectedly, there was no correlation between DEFB4 CN
variation and serum hBD-2 levels in patients, although a
positive correlation was found in controls (Figure 3). These
findings suggest that in the absence of infection, genetic
composition is the main factor controlling hBD-2 production,
as evidenced by the finding that CN variation accounts for
50% of the total variation in DEFB4 mRNA expression in
healthy subjects (Hollox et al., 2003). Given that hBD-2
peptide is an inducible rather than a constitutively expressed
peptide (Bissell et al., 2004), it is possible that the higher level
in patients is owing to the upregulation of expression by
T. rubrum rather than a variation in CN; i.e., regulation of
DEFB4 is largely governed by T. rubrum infection. These
results are in agreement with recent studies showing increased
hBD-2 expression in the superficial epidermal layers of
patients with tinea corporis (Brasch et al., 2014) or tinea
pedis (Kawai et al., 2006). In contrast, hBD-2 expression was
less evident in the stratum corneum under a high fungal
hyphae load, indicating that hBD-2 expression was suppressed
by infection (Jensen et al., 2007).
Another possible explanation for the high hBD-2 level in
patients is that T. rubrum infection introduces immunomodu-
latory factors—mainly cytokines—into the infected area and
that these factors induce hBD-2 production (Campos et al.,
2006; Pereira et al., 2013). Indeed, the level of IL-22
cytokine—which enhances antimicrobial peptide
production—was positively correlated with that of hBD-2 in
patients (Figure 3). Moreover, IL-22 was detected in a greater
number of patients and the serum level was about 3-fold
higher than that in controls (Figure 2). In CD3/28-stimulated T
cells, hBD-2 increases IL-22 production, which, in turn,
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Figure 3. Correlation between beta defensin 2 (DEFB4) copy number (CN) variation and serum human beta defensin (hBD)-2 and interleukin (IL)-22 levels.
Dermatophytosis patient subgroups are represented by different colors. (a) DEFB4 CN was positively correlated with hBD-2 level in controls (n¼ 195) but not in
patients (n¼ 247), and (b) negatively correlated with IL-22 level in patients but not in controls. (c) Serum hBD-2 and IL-22 levels were positively correlated in
patients but not in controls. Spearman’s rank correlation test was used to assess correlation. Po0.05 was considered significant (Bonferroni-corrected P values).
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induces hBD-2 expression through the Jak signal transducer
and activator of transcription (Jak-STAT) signaling pathway
(Aujla et al., 2008; Kanda and Watanabe, 2012). Furthermore,
IL-22 activates STAT3 in keratinocytes, whereas loss of STAT3
expression abrogated the inductive effect of IL-22 on genes
that regulate keratinocyte differentiation (Wolk et al., 2009). It
was suggested that STAT3 expression enhances the sensitivity
of keratinocytes to subsequent IL-22 exposure, thus providing
regulatory control through positive feedback.
IL-22 expression is reported to be induced by NF-kB,
CCAAT/enhancer-binding protein (C/EBP), or specificity pro-
tein 1 (Sp1); hBD-2-induced extracellular signal–regulated
kinase stimulates IL-22 production by activating Sp1 and
C/EBP expression and/or inducing their phosphorylation
(Kanda and Watanabe, 2012). It was therefore speculated
that altered serum IL-22 level is associated with DEFB4 CN
variation, which was examined in this study. Interestingly, IL-
22 level was higher in patients with low CN (p4) compared
with those with high (44) CN, whereas no relationship was
found in controls. One interpretation of these results is that IL-
22 has a protective role during T. rubrum infection, such that
the level of the antimicrobial hBD-2 is upregulated in patients
who have low DEFB4 CN and in whom the hBD-2 level is
insufficient for an immune response against T. rubrum, which
increases their susceptibility to infection. This is supported by a
study showing that hBD-2 inhibits T. rubrum growth in vitro
(Fritz et al., 2012). Consequently, T. rubrum may induce IL-22
production either directly or indirectly by stimulating other
factors known to enhance IL-22, such as tumor necrosis factor-
a and IL-1b (Sonnenberg et al., 2010), leading to the
upregulation of DEFB4 gene expression and increased
production of hBD-2. This could promote clearance of the
infection via antimicrobial and immunomodulatory activities,
and enhance IL-22 level through reciprocal regulation, thereby
eliminating the infection and restoring homeostasis. Indeed,
IL-22 has been shown to contribute to antifungal resistance at
epithelial surfaces by increasing the expression of other
antimicrobial genes that potentiate the function of IL-22 in a
positive feedback loop (Sabat et al., 2014). Putative STAT3-
binding sites were identified in an analysis of a 1000-base-pair
region of the DEFB4 promoter (Wolk et al., 2004), suggesting
that it is potentially regulated by IL-22 and that DEFB4 CN has
a significant role in modulating expression. That is, a higher
CN would provide more STAT3-responsive promoters that
are targeted by IL-22, thereby leading to higher hBD-2
peptide production. Specific transcriptional repressors may
also participate in cytokine-genomic responses and suppress
hBD-2 synthesis by blocking DEFB4 transcription. To
1,273 Participants were screened
for eligibility (2009–2013)
Included
639 Participants met the inclusion
criteria
Participants were distributed according to
physicians’ diagnosis
425 Patients suspected to
have dermatophytosis
35 Patients were further excluded due to
poor DNA quality and difficulty in DEFB4
CN variations, hBD-2 and IL-22 analysis
247 Patients were subcategorized according
to the clinical presentation
61 Tinea pedis 39 Lesions at multiple sites
64 Tinea unguium24 Tinea cruris
59 Tinea corporis
Microbiological tests
(T. rubrum)
282 Patients confirmed with
T. rubrum infection214 Healthy controls
19 Were further excluded
due to poor DNA quality
and difficulty in DEFB4
CN variations, hBD-2
and IL-22 analysis
195 Healthy controls
Unrelated German Caucasians  18 years. They had no history or 
current manifestation of systemic diseases such as diabetes mellitus; 
no atopic or skin disorders other than the suspected fungal skin 
infection; no HIV infection; were not pregnant and had not used antibiot-
ics or immunosuppressants within the previous 3 months; had no 
history of or were not currently undergoing chemotherapy or treatment 
with antifungal medication; had no trauma at the site of infection; were 
non-smokers; and had good body hygiene, with feet being washed on a 
daily basis.
Figure 4. Process of dermatophytosis study subject recruitment and assessment.
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investigate this possibility, it would be of interest to examine
the expression of multiprotein regulatory complexes at
promoter-proximal genomic response elements in individuals
who have high DEFB4 CN and low serum IL-22 levels; the
observed negative correlation between them raises several
questions regarding the role of DEFB4 CN in controlling gene
expression and systemic levels of other cytokines.
The negative association between DEFB4 CN and derma-
tophytosis was not observed in subgroups with X7 CN, with
the exception of the tinea pedis subgroup (Figure 1). One
explanation for this is that although higher CN can confer
immunity to dermatophytosis and, therefore, is a selective
advantage, genes with CN variation contain higher-than-
average frequencies of nonsynonymous mutations (Nguyen
et al., 2006). Thus, individuals with CNX7 may be
predisposed to mutations that could negatively affect the
activity of the DEFB4 gene against dermatophytosis.
However, given that CNX7 did protect against tinea pedis,
it would be of interest to investigate whether sites of infection
can be distinguished on a molecular basis, which would lead
to improved classification of dermatophytosis and therapeutic
management.
In this study, patients were categorized according to the
clinical presentation of dermatophytosis, and there were no
significant differences between these groups in terms of CN
distribution and systemic IL-22 level. Every effort was made to
match patients and controls by age and sex; however, the
majority of tinea cruris patients were relatively young male
individuals, consistent with the demographic data on the
prevalence of this form of dermatophytosis (Degreef, 2008).
Nonetheless, tinea cruris patients had a lower level of systemic
hBD-2 than those with other forms of tinea (Figure 2). This
may be because hBD-2 is variably expressed in different
regions of the human skin, with the scalp and plantar surfaces
having the highest expression, and the perineum, abdomen,
and chest expressing a low level of the peptide (Ali et al.,
2001). Sex differences in the tinea cruris subgroup, combined
group of patients, and controls was unrelated to serum hBD-2
levels (Supplementary Table S3 online), consistent with
another report showing that hBD-2 expression is not sex-
related (Wittersheim et al., 2013). Furthermore, age-related
changes in hBD-2 expression have been reported, with higher
expression being more frequently detected in older individuals
(Wittersheim et al., 2013), indicating that the lower hBD-2
level in the tinea cruris subgroup may have been a result of the
younger mean age of these patients.
In conclusion, an association was established
between DEFB4 CN variation and the occurrence of
T. rubrum–induced superficial dermatophytosis. The results
suggest that low DEFB4 CN is a risk factor for dermatophy-
tosis, with elevated IL-22 levels implicated in its pathogenesis.
Dermatophytosis candidate genes other than DEFB4,
such as Fc receptor gamma, which is used by the pattern
recognition receptor dectin-2 to induce innate immune
responses against T. rubrum (Sato et al., 2006; Nossent
et al., 2012), have also shown variable CN, and may simi-
larly contribute to the pathogenesis of dermatophyte infection.
A causal relationship between these factors should be verified
through prospective cohort studies, which should also be
undertaken in patient populations from different geogra-
phical regions. Identifying the genetic causes underlying
dermatophytosis will inform preventive treatments for persi-
stent forms such as tinea unguium that undermine the quality
of life of patients. The data for serum IL-22 levels and the
known contribution of IL-22 to protective immunity against
yeast infection raise the possibility of using IL-22 as a
therapeutic agent for dermatophytosis, which merits further
exploration.
MATERIALS AND METHODS
Study population
This cross-sectional study was approved by the Ethical Committee of
Jena University (no. 1940-01/07) and the protocol was in accordance
with the Declaration of Helsinki Principles, with all individuals
providing signed, informed consent before participation. Subjects
were enrolled at the Department of Dermatology from November
2009 to January 2014 and were interviewed and examined by two
experienced dermatologists. All efforts were made to reduce pheno-
typic heterogeneity by applying stringent criteria to the patient
selection process. All participants were unrelated German Cauca-
siansX18 years of age. They had no history or current manifestation
of systemic diseases such as diabetes mellitus; no atopic or skin
disorders other than the suspected fungal skin infection (cases with
T. rubrum infection); no HIV infection; were not pregnant and had not
used antibiotics or immunosuppressants within the previous 3
months; had no history of or were not currently undergoing
chemotherapy or radiotherapy or treatment with antifungal medica-
tion; had no trauma at the site of infection (for cases); were non-
smokers; and had good body hygiene, with feet being washed on a
daily basis.
Patients were diagnosed on the basis of the presence of clinical
signs of dermatophytosis and on mycologic evidence defined as a
fungal culture positive for T. rubrum. Clinical signs of dermatophy-
tosis were confirmed by direct microscopic examination of samples
with 10–20% potassium hydroxide and by culture on Sabouraud’s
dextrose agar with chloramphenicol (0.05%) and cycloheximide
(0.5%) or Sabouraud’s dextrose agar with chloramphenicol but
without cycloheximide. Diagnosis was confirmed only when both
clinical and laboratory criteria were met. Microbiological tests were
performed at Fungus Laboratory, Department of Dermatology, Jena
University Hospital. Patients were divided into subgroups according
to clinical presentation (Wagner and Sohnle, 1995): tinea corporis
(ringworm on the trunk); tinea cruris (ringworm of the groin); tinea
pedis (athlete’s foot); tinea unguium (onychomycosis and nail
infections); and patients with lesions at multiple sites, such as tinea
pedis and unguium, tinea pedis and manus/manuum, or tinea manus/
manuum with infected fingernails. Pooling subgroups together
yielded the combined group of patients. Controls and cases were
frequency matched for age and sex (Supplementary Table S1 online).
Controls were recruited after cases were enrolled, as the distribution
of matching factors—i.e., age and sex—was not known in advance.
Controls were examined physically to exclude clinical signs of
dermatophytosis (Figure 4). A total of 442 unrelated German
Caucasian participants comprising 247 dermatophytosis patients
(121 female and 126 male patients) and 195 controls (92 female
and 103 male patients) were included in the study.
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Diplotyping of DEFB4 CN variation
Genomic DNA isolation, quantification, and analysis of DEFB4 CN
variation (GenBank: AF040153.1) were carried out as previously
described (Abe et al., 2013; Jaradat et al., 2013). Briefly, genomic
DNA was isolated from peripheral blood using the QIAamp DNA
Blood Mini Kit (Qiagen, Hilden, Germany). A Nanodrop-1000
spectrophotometer (NanoDrop Technologies, Wilmington, DE) was
used to determine DNA concentration and quality; samples with
optical density 260/280 and 260/230 values of B1.8 and 2.0–2.2,
respectively, were used for analyses, which were performed by
individuals who were blinded to the clinical information. CN
variation was determined using duplex real-time PCR with TaqMan
CN target and RNase P reference assays (assay ID: 4403328)—i.e., by
relative quantification using the comparative CT (DDCT) method. PCR
was performed in 96-well plates on an ABI 7500 system (Applied
Biosystems, Foster City, CA). All assays were performed in
quadruplicate and included calibrator and negative control samples.
Reaction conditions were set at 95 1C for 10 minutes, followed by 40
cycles of 95 1C for 15 seconds and 60 1C for 1 minute.
Quantification of serum hBD-2 and IL-22 levels
Whole blood was collected at the time of enrollment between
7:00 hours and 12:00 hours, and the serum was separated and stored
as aliquots at  80 1C until used for analysis. Commercially available
ELISA kits were used according to the manufacturers’ recommenda-
tions to measure serum levels of hBD-2 (Beta Defensin-2 Kit with a
detection limit of 7.8 pg ml 1; Phoenix Europe GmbH, Karlsruhe,
Germany) and IL-22 (Human IL-22 Kit, with a detection limit of
2.7 pg ml 1; R&D Systems, Minneapolis, MN). Assays were performed
in duplicate. Samples that showed a value below the minimum
detectable dose for IL-22 were taken as 2.6 pg ml 1. An hBD-2-
positive control sample (B45–140 pg ml 1) was included in each
hBD-2 quantification assay. Measurements were carried out blindly
with respect to participants’ clinical characteristics and genetic data.
Statistical analysis
Statistical analyses were carried out using SPSS 22.0 for Windows
(SPSS, Chicago, IL). A normal probability (Q-Q) plot and the Shapiro–
Wilk test complementing the graphical analysis were used to deter-
mine whether data were normally distributed. Categorical variables
were compared using Pearson’s w2 test. To determine the strength of
the association between decreased DEFB4 CN and superficial derma-
tophytosis, we re-distributed the CN data according to the median
(o4, 4,44). The strength of associations was determined by calculat-
ing the OR and 95% confidence interval. Continuous variables were
compared using the nonparametric Mann–Whitney and Kruskal–
Wallis tests (for two- and multiple-group comparisons, respectively).
Correlations were analyzed by Spearman’s rank correlation (r).
Correlations were defined as follows: 1.00X(r)X0.650 or  1.00p(r)
p 0.650 (strong); 0.6504(r)X0.350 or  0.350X(r)4 0.650
(moderate); 0.3504(r)X0.200 or  0.200X(r)4 0.350 (weak);
and 0.2004(r)4 0.200 (none). A confidence interval for (r) was
established with Fisher’s z transformation. When dealing with multiple
comparisons, the P values were corrected with Bonferroni’s correction
by multiplying with the number of analyses. All P values were two-
sided and statistical significance was defined as Po0.05. The power
was estimated for different sample sizes by using the association
between higher DEFB CN and the relative risk of psoriasis reported in
one study (Hollox et al., 2008), which was the first to include both
Dutch and German participants. The effect sizes ranged from 0.25 to
0.4 for mean CN difference between cases or controls, whereas the
standard deviation of CNs was between 1.1 and 1.3. Power curves
were plotted for the unpaired t test for power calculation, assuming
equal variance in cases and controls and a significance level of 0.05
(Supplementary Figure 1 online). In the psoriasis study, the power
estimate ranged between 0.58 (based on a true difference of 0.25 and
standard deviation of 1.3) and 0.98 (based on a true difference of 0.4
and standard deviation of 1.1). Using the largest observed standard
deviation in this study (1.27 in cases), the power was 0.76 for a true
effect size of 0.25 and 0.94 for an effect size of 0.4.
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